SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending downwards, with the community actively discussing a potential share dilution and insider lockup expiration as possible catalysts. Concerns about management and valuation are prevalent, with some traders anticipating further declines while others see a buying opportunity amid oversold conditions. Despite the bearish sentiment, some community members express long-term bullishness, comparing it to similar fintech plays.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending after announcing a commercial agreement with Verizon for satellite-to-phone service by 2026, building on their existing partnership and sparking considerable excitement. The community is buzzing about the potential for seamless nationwide coverage and the stock's impressive gains, while also debating the impact of a recent stock offering and analyst ratings. Many express long-term bullish sentiment, viewing ASTS as a visionary play in the evolving space-based cellular connectivity sector.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals ($UPC) is trending due to discussions surrounding its low float and substantial cash reserves, leading to speculation about potential strategic moves. The community is drawing comparisons to other recent low-float runners, anticipating a similar breakout. Traders are closely monitoring for news catalysts that could trigger a significant price increase.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent $75 million investment, fueling speculation about the investor and its implications for the company's growth in AI connectivity. The community is focused on POET's potential in chip-to-chip communication and its role in addressing bottlenecks within AI data centers, viewing it as a key player in the broader AI hardware ecosystem.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending after securing new commercial orders and receiving a price target increase, fueling both bullish sentiment and skepticism about its valuation. Community chatter highlights concerns about a potential offering, while others believe the stock's upward trajectory is just beginning. The debate centers on whether RGTI's current price reflects its future potential in the quantum computing sector or if it's experiencing a speculative bubble.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

RNAZ is trending due to its recent acquisition of Polynoma and a secured $25 million financing, viewed as a significant catalyst despite potential dilution concerns. Community discussions revolve around the company's low float and potential for a squeeze, with some highlighting its cancer treatment advancements. The stock's volatility and upcoming Phase 2 trial are also key talking points.

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Xenetic Biosciences Inc

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss recent price volatility and potential short squeezes after news of the company's tokenization plans and a closed financing round. Traders are actively debating the stock's momentum, with some pointing to the company's low float and crypto-related initiatives, while others warn of potential pump-and-dump schemes. The conversation includes speculation about upcoming catalysts and potential for both significant gains and losses.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its potential for a short squeeze, driven by high short interest and recent positive news around AI adoption in the insurance sector. Community members are actively debating entry and exit points, with many expressing bullish sentiment and anticipating a move towards higher price targets. The stock's technicals and potential for disruption in the voice AI space are also fueling the conversation.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending amid renewed investor optimism, fueled by multi-launch contract news and overall excitement around the company's growth trajectory. Community members are actively discussing Neutron development progress and potential government contracts, while some caution against overvaluation given recent insider selling. The stock's strong performance is attracting both bullish sentiment and concerns about an upcoming pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%

AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.

Amgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the current list price via its direct-to-patient program in the U.S.The program, called AmgenNow, follows the Trump Administration’s push to lower drug prices in the U.S. Repatha will be available through the platform at a monthly cost of $239, Amgen <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/amgen-makes-repatha-available-through-amgennow-a-direct-to-patient-program-in-the-us-302575486.html">said</a>. The company noted that the program is open to all patients, including those who are uninsured or in high-deductible health plans or prefer to pay with cash or out of pocket.The company also noted that the new direct-to-patient price is the lowest among the economically developed countries and is being offered solely to U.S. patients.Amgen’s Repatha is indicated for lowering low-density lipoprotein cholesterol, commonly referred to as “bad” cholesterol.Shares of the company traded over 1% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.Amgen announced on Monday that it intends to make its direct-to-consumer platform accessible via the TrumpRx website, which was announced by the President last week and is slated for launch next year. The site will enable American consumers to purchase prescription drugs from pharmaceutical companies at a discount.In the second quarter of 2025, Repatha sales increased 31% year-over-year to $696 million, driven by 36% volume growth. This represented nearly 7.6% of the company’s overall revenue in the period.The announcement comes on the heels of President Trump sending letters to 17 drugmakers, including Amgen, in July, demanding that they lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations. Amgen announced on Monday that it would add other drugs to its AmgenNow platform.Separately, the medication savings platform GoodRx (GDRX) also said on Monday that patients can use the platform to access Repatha for $239 at more than 70,000 pharmacies U.S.-wide.AMGN stock is up by 14% this year but down by about 7% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

Amgen To Sell Cholesterol Drug For Approximately 60% Discount 

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 

Equity

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 


Hims & Hers Expands AI and Technology Focus to Advance Digital Care

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

U.S. equities edged lower in Monday’s midday trade as investors turned cautious ahead of Federal Reserve Chair Jerome Powell’s speech at the Jackson Hole symposium on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.08% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.19%.Here are the top stocks making the biggest moves in Monday’s midday trade:<a href="https://stocktwits.com/symbol/DAY">Dayforce Inc. (DAY)</a>Dayforce shares skyrocketed 26% in Monday’s midday trade after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/thoma-bravo-eyes-takeover-of-hr-software-firm-dayforce-report/chsaxunRdQJ">reports</a> suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.<a href="https://stocktwits.com/symbol/DAY">DAY stock</a> is down 8% year-to-date.<a href="https://stocktwits.com/symbol/APLD">Applied Digital Corp. (APLD)</a>Applied Digital shares gained over 14% in Monday’s midday trade after it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/this-data-center-stock-doubled-in-2025/chsOWqERdX9">announced</a> plans to begin construction of its next-generation $3 billion AI campus, Polaris Forge 2, in September.<a href="https://stocktwits.com/symbol/APLD">APLD stock</a> is up 111% year-to-date.<a href="https://stocktwits.com/symbol/GDRX">GoodRx Holdings Inc. (GDRX)</a>GoodRx shares surged over 35% in Monday’s midday trade after Novo Nordisk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cuts-ozempic-cost-to-499-dollars-per-month-for-self-paying-patients/chsOfKDRdXE">announced</a> a collaboration with the drug savings platform to provide self-paying eligible type 2 diabetes patients with access to Ozempic at $499.<a href="https://stocktwits.com/symbol/GDRX">GDRX stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/FSLR">First Solar Inc. (FSLR)</a>First Solar shares surged nearly 9% in Monday’s midday trade as investors cheered the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/solar-incentives-treasury-clears-the-air-fslr-run-enph-nee-stocks-in-focus/chsOJX1RdQy">clarity offered</a> by the U.S. Treasury Department and the Internal Revenue Service regarding wind and solar incentives. Shares of other clean energy companies, like SolarEdge Technologies Inc. (SEDG), Sunrun Inc. (RUN), Enphase Energy Inc. (ENPH), and NextEra Energy Inc. (NEE), also rose.<a href="https://stocktwits.com/symbol/FSLR">FSLR stock</a> is up 23% year-to-date.<a href="https://stocktwits.com/symbol/WULF">TeraWulf Inc. (WULF)</a>TeraWulf shares surged more than 11% in Monday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/terawulf-launches-400-million-convertible-note-offering/chsO7yLRdQx">announced</a> plans to raise $400 million through a private offering of convertible senior notes due in 2031. Alphabet Inc.’s (GOOG/GOOGL) Google also extended its backstop to $3.2 billion from $1.8 billion, with its stake in the company increasing to nearly 14%.<a href="https://stocktwits.com/symbol/WULF">WULF stock</a> is up 76% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-warns-investors-be-prepared-goldilocks-dominating-equity-markets/chsOiYdRdXg">JPMorgan Warns Investors To Brace For Incoming Volatility, Says ‘Goldilocks’ Narrative Still Dominating Markets: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Dayforce, Applied Digital, GoodRx, First Solar, TeraWulf: Stocks Making The Biggest Moves Today

Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.

Danish drugmaker Novo Nordisk (NVO) has announced that it will allow self-paying eligible type 2 diabetes patients access to its Ozempic for $499 per month starting Monday via multiple platforms, including drug savings platform GoodRx (GDRX).The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost. The offer will also be available through the company’s online pharmacy, NovoCare, as well as the drug’s official website.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-full-year-guidance/cho9UwAR5yE">NVO</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. Shares of the company traded 5% higher on Monday morning at the time of writing.The offer comes as the company battles the compounding of its blockbuster medicines. Last month, Novo lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and Ozempic for the second half of the year. While the U.S. Food and Drug Administration has prohibited mass compounding for the active component in Wegovy and Ozempic called Semaglutide, unsafe and unlawful mass compounding has continued, the company said, citing its market research.“We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many. This is why we felt it was important to make Ozempic, the GLP-1 with the broadest range of FDA-approved indications for adults with type 2 diabetes, more affordable to those without insurance who deserve the real thing," <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916418">said</a> Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc.As part of Novo’s collaboration with GoodRx, self-paying patients can get all strengths of both Wegovy and Ozempic for $499 per month through the GoodRx platform. Eligible patients can use GoodRx to self-pay for Ozempic and Wegovy pens for $499 per month at over 70,000 retail pharmacies nationwide, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-announces-collaboration-novo-nordisk-expand-access">said</a>. Shares of <a href="https://stocktwits.com/symbol/GDRX">GDRX </a>traded 31% higher following the news.While NVO stock is down by 37% this year, GDRX is up by 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT">LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients

The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost.

Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates

GoodRx (GDRX) delivered earnings and revenue surprises of -10.00% and -1.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Q2 Earnings and Revenues Beat Estimates

Surgery Partners (SGRY) delivered earnings and revenue surprises of +6.25% and +0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?

OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.

GDRX vs. HQY: Which Stock Is the Better Value Option?

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx Holdings Inc - Ordinary Shares - Class A

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

GDRX GoodRx Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GDRX News